551.43
Idexx Laboratories Inc stock is traded at $551.43, with a volume of 216.17K.
It is down -0.62% in the last 24 hours and down -1.02% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$554.94
Open:
$554.09
24h Volume:
216.17K
Relative Volume:
0.37
Market Cap:
$43.46B
Revenue:
$4.45B
Net Income/Loss:
$1.10B
P/E Ratio:
40.57
EPS:
13.591
Net Cash Flow:
$1.06B
1W Performance:
-1.88%
1M Performance:
-1.02%
6M Performance:
-19.89%
1Y Performance:
+4.50%
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
550.89 | 43.32B | 4.45B | 1.10B | 1.06B | 13.59 |
|
TMO
Thermo Fisher Scientific Inc
|
504.19 | 182.91B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
193.19 | 133.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
A
Agilent Technologies Inc
|
135.82 | 37.18B | 7.23B | 1.41B | 1.09B | 4.979 |
|
NTRA
Natera Inc
|
270.18 | 37.23B | 2.50B | -226.32M | 71.51M | -1.6412 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
Is IDEXX Laboratories stock underperforming the Nasdaq? - MSN
IDEXX Laboratories, Inc. Actuals & Estimates (VIE:IDXX) - TradingView
IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock - Ad-hoc-news.de
Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – DUS:IX1 - TradingView
Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15 - TIKR.com
Price to book forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Enterprise value to revenue forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories analyst consensus stays firm, shares trade below recent high - Ad-hoc-news.de
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SNAP 4Dx Plus Test from IDEXX Laboratoriesquick tick-borne screening in minutes - Ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. - marketscreener.com
A Small Upgrade Could Have a Big Impact for IDEXX Customers - Insider Monkey
IDEXX Laboratories StockSaturday deep dive into the long-term business model - Ad-hoc-news.de
New diagnostic test for kidney injury - DVM360
IDEXX Laboratories Sharesanalyst consensus stays cautious - Ad-hoc-news.de
IDEXX Laboratories Stock Is Down 16% in 2026: Does the Q1 Beat Make It a Buy at $562? - TIKR.com
Why IDEXX Neo practice software wants to disappear into the background - AD HOC NEWS
IDEXX Laboratories Inc (IDXX) Institutional Confidence - TradingKey
IDEXX Laboratories Inc (IDXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IDEXX Laboratories Inc (IDXX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEXX Laboratories Inc (IDXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDEXX Laboratories Inc (IDXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IDEXX Laboratories Inc (IDXX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 96/100 - GuruFocus
IDEXX Laboratories Inc (IDXX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories Inc (IDXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IDEXX Laboratories Inc. stock rises Monday, still underperforms market - MarketWatch
IDEXX Laboratories Inc Stock (US45167R1041): valuation metrics in focus for S&P 500 diagnostics name - Ad-hoc-news.de
IDEXX Laboratories Stock (US45168D1046): Technical signal after 38-day moving average crossover - AD HOC NEWS
IDEXX Laboratories Stock (US45168D1046): Valuation and fundamentals in focus for S&P 500 pet-health - AD HOC NEWS
IDEXX Laboratories stock (US45168D1046): Double-digit jump after strong earnings and Nasdaq 100 outp - Ad-hoc-news.de
IDEXX Laboratories Stock’s 63% Gross Margin Story: Here’s What the Numbers Say About a $909 Target - TIKR.com
Is It Too Late to Buy IDEXX Laboratories Inc (IDXX) After 3.2% R - GuruFocus
Is IDEXX Laboratories Stock Underperforming the Nasdaq? - Barchart.com
Idexx appears to have plate-reading cameras monitoring Maine properties - The Portland Press Herald
BARON GROWTH FUND's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
Is Wall Street bullish or bearish on IDEXX Laboratories stock? - MSN
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 26% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
IDEXX Laboratories touts AI push, inVue Dx momentum at Stifel conference - MSN
Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
IDEXX Parasite Test Expansion Links Zoonotic Risk And Valuation Debate - Yahoo Finance
IDEXX (IDXX) EVP Fennell reports RSU vesting and tax share withholding - Stock Titan
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unveiling 25.84% Potential Upside in the Diagnostics Market - DirectorsTalk Interviews
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):